Population Disparities in Health Equity and Managed Care
EP: 1.The Impact of Multiple Sclerosis on Quality of Life
EP: 2.Increased Prevalence of MS in Various Patient Subpopulations
EP: 3.The Importance of Early Diagnosis and Treatment in Patients with MS
EP: 4.Future Directions in Health Equity for MS Treatment
EP: 5.Challenges to Equal Access in MS Treatment
EP: 6.Impact of Limited Care for Patients with Chronic Disease
EP: 7.Population Disparities in Health Equity and Managed Care
EP: 8.Implications of Treatment Affordability Issues
EP: 9.Importance of Payer/Clinician Agreement in Patient Treatment
EP: 10. Practical Steps to Mitigating Health Iniquity
Results from the analysis showed that the Medicaid group experienced lower pharmacy-related costs, which could be attributed to DMT use: 32.5% of Medicaid patients used DMTs versus 52.1% of commercial patients. (19) The authors noted that insufficient care coordination and patient education regarding correct use of DMTs could contribute to the higher rate of hospitalizations and MS-related complications experienced by the Medicaid group. (19)
In addition to a lack of care coordination and patient education regarding DMTs, racial and ethnic minority groups may experience coverage barriers in accessing the DMTs they need for optimal outcomes. Coverage criteria varies by insurance provider; therefore, patients receiving drug coverage from different providers may experience different levels of access and coverage for DMTs.20 High copays and lack of coverage for certain therapies limit treatment options for most patients. (21)
